Phaseline

Targets › FLT1

FLT1 (Vascular endothelial growth factor receptor 1): drug programs, companies and trials

24 programs from 23 companies in 295 trials: 215 Phase 2, 40 Phase 1, 34 Phase 3, 6 Phase 4; Oncology, Other, Ophthalmology; next expected readout Dec 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Acts as a positive regulator of postnatal retinal hyaloid vessel regression (By similarity). (UniProt, P17948)

Open in Phaseline: the race on FLT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaFruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 4Colorectal CancerOct 2027
Adverum BiotechnologiesIxo-vec (ixoberogene soroparvovec)
Intravitreal gene therapy expressing soluble fms-like tyrosine kinase-1 (sFlt-1), a VEGF t
FLT1Phase 3Neovascular Age-Related Macular Degeneration (nAMD); Neovascular Age-Related Macular Degeneration (nAMD) Wet AMDDec 2026
Shanghai Junshi Bioscience Co., Ltd.Lenvatinib mesylate
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Advanced Hepatocellular Carcinoma (HCC); Intrahepatic CholangiocarcinomaDec 2026
Ocular TherapeutixAxitinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Neovascular Age-related Macular Degeneration; Non-Proliferative Diabetic Retinopathy; Neovascular Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD) …Jan 2027
University Hospital, BordeauxPD-1/PD-L1 ICI + VEGFR-TKI combination
PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor
PDCD1, CD274, KDR, FLT1, FLT4Phase 3Metastatic Renal Cell CarcinomaJan 2027
Merck & Co. (MSD)Lenvatinib (MK-7902)
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Carcinoma, Renal Cell; Solid Tumors; Neoplasm Malignant; Esophageal Squamous Cell Carcinoma …Feb 2027
Jiangsu HengRui MedicineFamitinib
Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
KIT, FLT1, FLT3, PDGFRB, PDGFRAPhase 3Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm …May 2027
AO GENERIUMGNR-139
Aflibercept biosimilar; VEGF-A and PlGF antagonist; binds VEGFR1 and VEGFR2
FLT1, KDR, FLT4Phase 3nAMDMay 2028
Hutchmedfruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Advanced Endometrial Cancer; Advanced Renal Cell CarcinomaJan 2029
Alliance for Clinical Trials in OncologyTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 3Clear Cell Renal Cell CarcinomaNov 2037
Avalyn PharmaNintedanib (AP02)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer …Dec 2026
Sun Yat-sen UniversityAnlotinib Hydrochloride
Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET
VEGFR, PDGFRA, PDGFRB, FLT1, KITPhase 2GlioblastomaDec 2026
Henan Cancer HospitalLenvatinib Mesylate
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2EffectivenessDec 2026
Chipscreen BiosciencesIbcasertib
Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor
AURKB, FLT1, FLT4, KDRPhase 2Pancreatic Ductal AdenocarcinomaFeb 2027
City of Hope Medical CenterLenvatinib Mesylate
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2Advanced Pancreatic Ductal Adenocarcinoma; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Apr 2027
MannkindNintedanib (MNKD-201)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary FibrosisDec 2027
CriteriumFruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2Colorectal Cancer; Metastatic Oesogastric Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma …Dec 2027
HutchmedSurufatinib
Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor
FGFR1, FLT1, FLT4, KDRPhase 2Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma …May 2028
M.D. Anderson Cancer CenterTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 2Renal Cell CarcinomaNov 2028
University of FloridaTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1Bile Duct CancerDec 2026
AstraZenecacediranib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
KIT, PDGFRB, PDGFRA, FLT1, FLT4Phase 1Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer …Dec 2026
Betta PharmaceuticalsX-82
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 1DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib …Jan 2027
Sichuan UniversityDual-targeting VEGFR1/PD-L1 CAR-T cells
Bispecific CAR-T cells targeting VEGFR1 and PD-L1
FLT1, CD274Phase 1Malignant Peritoneal EffusionJun 2027
National Cancer Institute (NCI)Tivozanib (AV-951)
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1CholangiocarcinomaDec 2028

Conditions

Hepatocellular Carcinoma (12) Colorectal Cancer (11) Hepatocellular Carcinoma Non-resectable (7) Renal Cell Carcinoma (6) Intrahepatic Cholangiocarcinoma (6) Gastric Cancer (6) Metastatic Renal Cell Carcinoma (6) HCC (5) Clear Cell Renal Cell Carcinoma (5) Intrahepatic Cholangiocarcinoma (Icc) (5) Hepatocellular Carcinoma (HCC) (5) HCC - Hepatocellular Carcinoma (4)

Modalities

small molecule (11), mixed (11), other (1), antibody (1)

Companies

Hutchmed (2) Merck & Co. (MSD) (1) University Hospital, Bordeaux (1) Takeda (1) AO GENERIUM (1) Chipscreen Biosciences (1) National Cancer Institute (NCI) (1) Adverum Biotechnologies (1) Avalyn Pharma (1) Alliance for Clinical Trials in Oncology (1) Shanghai Junshi Bioscience Co., Ltd. (1) University of Florida (1) Mannkind (1) Sun Yat-sen University (1) Sichuan University (1) Ocular Therapeutix (1) AstraZeneca (1) Jiangsu HengRui Medicine (1) City of Hope Medical Center (1) Henan Cancer Hospital (1)

Related targets

FLT4 (20) KDR (19) PDGFRB (10) KIT (7) PDGFRA (6) CD274 (2) PDCD1 (1) AURKB (1) VEGFR (1) FLT3 (1) FGFR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.